Zealand Pharma AS (OCSE:ZEAL) Institutional Ownership : 54.83% (As of Mar. 02, 2025)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma AS Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zealand Pharma AS's institutional ownership is 54.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zealand Pharma AS's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zealand Pharma AS's Float Percentage Of Total Shares Outstanding is 0.00%.

Zealand Pharma AS Institutional Ownership Historical Data

The historical data trend for Zealand Pharma AS's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma AS Institutional Ownership Chart

Zealand Pharma AS Historical Data

The historical data trend for Zealand Pharma AS can be seen below:

	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31
Institutional Ownership	44.13	43.64	40.24	42.57	42.94	47.89	48.21	47.76	54.86	54.83

Zealand Pharma AS Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Zealand Pharma AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma AS (OCSE:ZEAL) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.